Nothing Special   »   [go: up one dir, main page]

Chernov et al., 2023 - Google Patents

Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR …

Chernov et al., 2023

View HTML
Document ID
5456914405104996870
Author
Chernov V
Rybina A
Zelchan R
Medvedeva A
Bragina O
Lushnikova N
Doroshenko A
Usynin E
Tashireva L
Vtorushin S
Abouzayed A
Rinne S
Sörensen J
Tolmachev V
Orlova A
Publication year
Publication venue
Cancers

External Links

Snippet

Simple Summary Prostate and breast cancers are the most common malignancies. Accurate diagnosis and staging of diseases are important for the prognosis and determination of treatment tactics. The gastrin-releasing peptide receptor is overexpressed in over 80% of …
Continue reading at www.mdpi.com (HTML) (other versions)

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay
    • G01N33/574Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407Specifically defined cancers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/0493Steroids, e.g. cholesterol, testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06FELECTRICAL DIGITAL DATA PROCESSING
    • G06F19/00Digital computing or data processing equipment or methods, specially adapted for specific applications
    • G06F19/30Medical informatics, i.e. computer-based analysis or dissemination of patient or disease data
    • GPHYSICS
    • G06COMPUTING; CALCULATING; COUNTING
    • G06QDATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
    • G06Q50/00Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
    • G06Q50/10Services
    • G06Q50/22Health care, e.g. hospitals; Social work

Similar Documents

Publication Publication Date Title
Lenzo et al. Review of gallium-68 PSMA PET/CT imaging in the management of prostate cancer
Vahidfar et al. Theranostic advances in breast cancer in nuclear medicine
Awenat et al. Diagnostic role of 18F-PSMA-1007 PET/CT in prostate cancer staging: a systematic review
Chernov et al. Phase I trial of [99mTc] Tc-maSSS-PEG2-RM26, a bombesin analogue antagonistic to gastrin-releasing peptide receptors (GRPRs), for SPECT imaging of GRPR expression in malignant tumors
Kaloudi et al. NeoBOMB1, a GRPR-antagonist for breast cancer theragnostics: First results of a preclinical study with [67Ga] NeoBOMB1 in T-47D cells and tumor-bearing mice
Plichta et al. Prostate-specific membrane antigen (PSMA) theranostics for treatment of oligometastatic prostate cancer
Hadebe et al. The role of PET/CT in breast cancer
Ma et al. PET/CT for predicting occult lymph node metastasis in gastric cancer
Kaewput et al. Update of PSMA theranostics in prostate cancer: current applications and future trends
Nock et al. [99mTc] Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes
Wong et al. 64Cu-SAR-bombesin PET-CT imaging in the staging of estrogen/progesterone receptor positive, HER2 negative metastatic breast cancer patients: safety, dosimetry and feasibility in a Phase I trial
Vahidfar et al. A review of nuclear medicine approaches in the diagnosis and the treatment of gynecological malignancies
Tan et al. PSMA PET imaging and therapy in adenoid cystic carcinoma and other salivary gland cancers: a systematic review
Lundmark et al. Preclinical characterisation of PSMA/GRPR-targeting heterodimer [68Ga] Ga-BQ7812 for PET diagnostic imaging of prostate cancer: A step towards clinical translation
Abouzayed et al. Preclinical evaluation of 99mTc-labeled GRPR antagonists maSSS/SES-PEG2-RM26 for imaging of prostate cancer
Farr et al. Imaging modalities for early detection of pancreatic cancer: Current state and future research opportunities
Klain et al. Advances in functional imaging of differentiated thyroid cancer
Taralli et al. PET/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application—a literature review
Gruber et al. Imaging properties and tumor targeting of 68ga-neobomb1, a gastrin-releasing peptide receptor antagonist, in gist patients
Bragina et al. Direct intra-patient comparison of scaffold protein-based tracers,[99mTc] Tc-ADAPT6 and [99mTc] Tc-(HE) 3-G3, for imaging of HER2-Positive breast cancer
Baun et al. Preclinical evaluation of the copper-64 labeled GRPR-antagonist RM26 in comparison with the cobalt-55 labeled counterpart for PET-imaging of prostate cancer
Ferrari et al. [18F] fluciclovine vs.[18F] fluorocholine positron emission tomography/computed tomography: a head-to-head comparison for early detection of biochemical recurrence in prostate cancer patients
Ćwikła et al. Initial experience of clinical use of [99mTc] Tc-PSMA-T4 in patients with prostate cancer. A pilot study
Jetty et al. Prostate Cancer—PET Imaging Update
Coria-Domínguez et al. [99mTc] Tc-iFAP radioligand for SPECT/CT imaging of the tumor microenvironment: kinetics, radiation dosimetry, and imaging in patients